The Week

LABU fell 18.19% this week to close at $198.86, underperforming the S&P 500 by about 16.24 percentage points. The fund opened Monday at $241.52 and slid through the week. Thursday brought a brief rebound to $222.94, but Friday recorded a 10.79% single-day drop and closed near the week’s low of $196.56. The weekly range was 19.92%, a one-way move lower that accelerated into the close.

SPDR S&P Biotech This Week

The underlying SPDR S&P Biotech slipped 6.15% to finish at $144.32. It opened Monday at $153.43 and drifted lower across all five sessions, touching a low of $143.849 on Friday before ending near that level. The weekly range was 6.69%, with only Thursday offering a modest 2.05% bounce in an otherwise steady slide.

Leverage & Decay

LABU aims to track three times the daily move of the SPDR S&P Biotech. With the underlying down 6.15% for the week, the theoretical 3x outcome is about -18.45%. LABU closed at -18.19%, a gap of +0.26 percentage points. The difference comes from daily rebalancing: the product mirrors single-day moves, not the cumulative weekly return. Because most sessions moved in one direction this week, the rebalancing drag stayed small. If volatility picks up and the underlying starts to chop, the daily reset can amplify the gap, and long-term returns will not necessarily equal three times the underlying’s cumulative move.

SPDR S&P Biotech News

Biotech news this week clustered around a few storylines. AbbVie’s SKYRIZI subcutaneous induction dosing for Crohn’s disease moved into FDA review. Vir Biotechnology and Gilead reached a collaboration on T-cell engagers worth up to $1.9 billion. Moderna kept rallying on cancer vaccine expectations, with some call options up between 113% and 132% during the week. At the same time, large-cap pharma attracted defensive flows as AI names sold off, and Biogen traded mixed after JPMorgan upgraded it. These developments coincided with a choppy, lower-trending week for the underlying, without implying causation.

The Week Ahead

Next week’s macro calendar includes the NAHB housing market index on 19 October, US housing starts and building permits on 20 October, and EIA crude inventory data on 21 October. On the biotech side, the options activity around Moderna and the cancer vaccine narrative remain in play, and any further swings there could feed into sentiment for the SPDR S&P Biotech. For LABU, the focus stays on whether the underlying can stabilise after this week’s pullback.

In Short

LABU dropped roughly 18.19% this week under the combined weight of a falling underlying and 3x leverage, lagging the S&P 500 by more than 16 percentage points. The biotech tape was event-heavy but still skewed lower, with defensive flows into large-cap pharma and speculative interest in mRNA names sitting side by side. The question now is whether the SPDR S&P Biotech can steady itself at these levels, and whether the coming macro data keeps pressure on the sector.

This article is generated by LongbridgeAI from market data, for information only and not investment advice.